Indaptus Therapeutics, Inc. Operating Cash Flow
Indaptus Therapeutics, Inc. (INDP) reported Operating Cash Flow of -$8.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.93M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$7.01M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.19M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.57M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$14.82M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$12.32M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$13.41M.
- Indaptus Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$13.08M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$8.94M 10-Q · filed 2026-08-13 | -$12.13M derived: sum of 3 quarters · filed 2026-08-13 | -$14.70M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$7.01M 10-Q · filed 2026-05-15 | -$10.20M derived: sum of 2 quarters · filed 2026-05-15 | -$12.77M derived: sum of 3 quarters · filed 2026-05-15 | -$16.79M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$5.76M derived: sum of 2 quarters · filed 2026-03-17 | -$9.78M derived: sum of 3 quarters · filed 2026-08-13 | -$14.82M 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.59M derived: sum of 2 quarters · filed 2026-08-13 | -$11.63M 10-Q · filed 2025-11-12 | -$15.03M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$9.07M 10-Q · filed 2026-08-13 | -$12.46M derived: sum of 3 quarters · filed 2026-08-13 | -$14.97M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$5.05M 10-Q · filed 2026-05-15 | -$8.44M derived: sum of 2 quarters · filed 2026-05-15 | -$10.96M derived: sum of 3 quarters · filed 2026-05-15 | -$13.43M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$5.91M derived: sum of 2 quarters · filed 2026-03-17 | -$8.39M derived: sum of 3 quarters · filed 2026-03-17 | -$12.32M 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$4.99M derived: sum of 2 quarters · filed 2025-11-12 | -$8.93M 10-Q · filed 2025-11-12 | -$11.53M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$6.41M 10-Q · filed 2025-08-13 | -$9.02M derived: sum of 3 quarters · filed 2025-08-13 | -$12.75M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$3.94M 10-Q · filed 2025-05-14 | -$6.54M derived: sum of 2 quarters · filed 2025-05-14 | -$10.27M derived: sum of 3 quarters · filed 2025-05-14 | -$12.38M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$6.34M derived: sum of 2 quarters · filed 2025-03-13 | -$8.44M derived: sum of 3 quarters · filed 2025-03-13 | -$13.41M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$5.84M derived: sum of 2 quarters · filed 2024-11-12 | -$10.80M 10-Q · filed 2024-11-12 | -$13.01M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$7.07M 10-Q · filed 2024-08-12 | -$9.28M derived: sum of 3 quarters · filed 2024-08-12 | -$13.88M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$4.96M 10-Q · filed 2024-05-08 | -$7.17M derived: sum of 2 quarters · filed 2024-05-08 | -$11.77M derived: sum of 3 quarters · filed 2024-05-08 | -$14.92M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$6.81M derived: sum of 2 quarters · filed 2024-03-13 | -$9.96M derived: sum of 3 quarters · filed 2024-03-13 | -$13.08M 10-K · filed 2024-03-13 | |
| 2022-09-30 | -$4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$7.75M derived: sum of 2 quarters · filed 2023-11-06 | -$10.87M 10-Q · filed 2023-11-06 | -$14.41M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | -$3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$6.27M 10-Q · filed 2023-08-14 | -$9.81M derived: sum of 3 quarters · filed 2023-08-14 | -$15.44M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$3.12M 10-Q · filed 2023-05-11 | -$6.66M derived: sum of 2 quarters · filed 2023-05-11 | -$12.29M derived: sum of 3 quarters · filed 2023-05-11 | -$13.58M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$9.17M derived: sum of 2 quarters · filed 2023-03-17 | -$10.46M derived: sum of 3 quarters · filed 2023-03-17 | -$11.29M 10-K · filed 2023-03-17 | |
| 2021-09-30 | -$5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$6.93M derived: sum of 2 quarters · filed 2022-11-10 | -$7.75M 10-Q · filed 2022-11-10 | -$8.71M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$2.12M 10-Q · filed 2022-08-08 | -$7.40M 10-Q · filed 2021-08-16 | -$3.08M derived: sum of 3 quarters · filed 2022-08-08 | $1.37M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$825.58K 10-Q · filed 2022-05-12 | -$1.78M derived: sum of 2 quarters · filed 2022-05-12 | $2.67M derived: sum of 3 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$957.03K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $3.49M derived: sum of 2 quarters · filed 2022-03-21 | -$3.32M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $4.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$2.37M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$6.82M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |